Navigation Links
Vista Partners Initiates Coverage on ADVENTRX Pharmaceuticals, Inc.; Target Price $7.50
Date:6/22/2011

SAN FRANCISCO, June 22, 2011 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX) ("The Company" or "ANX"); with a twelve month target price of $7.50. Ross Silver, Principal Analyst at Vista Partners stated, “ANX has a diverse late stage clinical pipeline with two clinical candidates that could serve multi-billion dollar markets and one candidate with a Prescription Drug User Fee Act, or PDUFA, goal date of September 1, 2011 that could lead to approval by FDA as early as this year. ANX is developing a study protocol for ANX-514, a novel emulsion formulation of the chemotherapy drug docetaxel which serves a multi-billion dollar market. The Company is preparing ANX-514 for submission to the FDA and intends to continue discussions with the FDA regarding the planned Phase 3 clinical study and other requirements for approval of ANX-514. The company is developing its protocol for a pivotal Phase III trial scheduled to begin in 2012." Mr. Silver continues, "In April 2011, ANX completed the acquisition of SynthRx, Inc. SynthRx's lead product candidate is a novel, purified, rheologic and antithrombotic compound, purified poloxamer 188, which ANX is developing as ANX-188. Initially, ANX is developing ANX-188 as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis and, if ANX is able to reach agreement with FDA on a study protocol on a timely basis, ANX may initiate a Phase 3 clinical trial of ANX-188 for that indication in 2012." Mr. Silver concludes, "In November 2010, ANX submitted a new drug application, or NDA, for Exelbine™, or ANX-530, a novel emulsion formulation of the chemotherapy drug vinorelbine (Navelbine®), to the U.S. Food and Drug Administration, or FDA, and in January 2011, ANX announced that the FDA accepted the Exelbine™ NDA for filing and established a Prescription Drug User Fee Act, or PDUFA, goal date of September 1, 2011 to finish its review of the Exelbine™ NDA."

To download a FREE copy of the ADVENTRX Pharmaceuticals, Inc. research report, please visit http://www.vistapglobal.com and click the "download research" icon to gain access to the report.

About Vista Partners:

Vista Partners LLC, founded in 2005, is a Registered Investment Advisor in the States of California and Oregon. The firm's professional staff has backgrounds in finance, corporate communications and investment banking. Vista Partners LLC has built a name for itself in the small cap space due to its selection of profitable investment ideas.

Disclaimer & Disclosure:

For a full list of disclaimers and disclosures, please visit our website www.vistapglobal.com or click here.

Contact:
877.215.4813 or info@vistapglobal.com


'/>"/>
SOURCE Vista Partners
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
3. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
4. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
5. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
6. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
7. NeoVista, Inc. Presents New Data on Its Novel Wet AMD Therapy at AAO
8. Siemens Healthcare Diagnostics Launches B12, Folate, and Ferritin Tests on Its Dimension vista Intelligent Lab System
9. NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
10. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
11. FDA Grants NeoVistas Request to Expand CABERNET Trial to 30 Sites in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ... Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) expired ... Time). As previously announced on May 31, ... merger agreement under which Jazz Pharmaceuticals has commenced a ...
(Date:6/26/2016)... LAS VEGAS , June 26, 2016 ... movement to value-based care operating models within the health ... that enable greater financial efficiency , Deloitte offers ... address the key business issues impacting efficient cost optimization: ... alignment , These services facilitate better outcomes and ...
(Date:6/24/2016)... 2016  Collagen Matrix, Inc., ("Collagen Matrix") the ... of collagen and mineral based medical devices for ... Bill Messer has joined the company as ... the growing portfolio of oral surgery, neurosurgery, orthopaedic ... joins the Collagen Matrix executive team as an ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
Breaking Medicine News(10 mins):